➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Harvard Business School
Johnson and Johnson
Medtronic
McKesson

Last Updated: October 25, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Thymosin beta-4

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Thymosin beta-4?

Thymosin beta-4 is an investigational drug.

There have been 11 clinical trials for Thymosin beta-4. The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2011.

The most common disease conditions in clinical trials are Keratoconjunctivitis Sicca, Myocardial Infarction, and Dry Eye Syndromes. The leading clinical trial sponsors are RegeneRx Biopharmaceuticals, Inc., Beijing Northland Biotech. Co., Ltd., and sigma-tau i.f.r. S.p.A.

There are nine US patents protecting this investigational drug and fifty-nine international patents.

Recent Clinical Trials for Thymosin beta-4
TitleSponsorPhase
A Phase 1b Study of the Intravenous Administration of Thymosin Beta 4 in Healthy VolunteersBeijing Northland Biotech. Co., Ltd.Phase 1
A Phase 1a Study of the Intravenous Administration of Thymosin Beta 4 in Healthy VolunteersBeijing Northland Biotech. Co., Ltd.Phase 1
A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial InfarctionRegeneRx Biopharmaceuticals, Inc.Phase 2

See all Thymosin beta-4 clinical trials

Clinical Trial Summary for Thymosin beta-4

Top disease conditions for Thymosin beta-4
Top clinical trial sponsors for Thymosin beta-4

See all Thymosin beta-4 clinical trials

US Patents for Thymosin beta-4

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Thymosin beta-4   Start Trial Muscle cell patches and uses therefor ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (Tucson, AZ) THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (Washington, DC)   Start Trial
Thymosin beta-4   Start Trial Composition for treating ischemic diseases or neuroinflammatory diseases, comprising secretome of neural precursor cells as active ingredient S-BIOMEDICS (Seoul, KR)   Start Trial
Thymosin beta-4   Start Trial Materials and methods for diagnosis and treatment of Alzheimer's disease ELECTROPHORETICS LIMITED (London, GB)   Start Trial
Thymosin beta-4   Start Trial Methods for identifying and using maintenance genes Affymetrix, Inc. (Santa Clara, CA)   Start Trial
Thymosin beta-4   Start Trial Controlled release formulations Aegis Therapeutics, LLC (San Diego, CA) The UAB Research Foundation (Birmingham, AL)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Thymosin beta-4

Drugname Country Document Number Estimated Expiration Related US Patent
Thymosin beta-4 Australia 2014331947 2033-10-09   Start Trial
Thymosin beta-4 Canada 2927062 2033-10-09   Start Trial
Thymosin beta-4 European Patent Office 3055028 2033-10-09   Start Trial
Thymosin beta-4 Japan 2016536103 2033-10-09   Start Trial
Thymosin beta-4 Japan 2019141065 2033-10-09   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Harvard Business School
Johnson and Johnson
Medtronic
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.